Literature DB >> 19854050

Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.

Bin Su1, Shiuan Chen.   

Abstract

A series of COX-2 selective inhibitor nimesulide derivatives were synthesized. Their anti-cell proliferation activities were evaluated with a long-term estrogen deprived MCF-7aro (LTEDaro) breast cancer cell line, which is the biological model of aromatase inhibitor resistance for hormone-dependent breast cancer. Compared to nimesulide which inhibited LTEDaro cell proliferation with an IC(50) at 170.30 microM, several new compounds showed IC(50) close to 1.0 microM.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19854050      PMCID： PMC2783870          DOI： 10.1016/j.bmcl.2009.09.109

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  22 in total

Review 1.  Aromatase inhibitors in breast cancer.

Authors:  Ian E Smith; Mitch Dowsett
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

2.  Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells.

Authors:  R X Song; R J Santen; R Kumar; L Adam; M-H Jeng; S Masamura; W Yue
Journal:  Mol Cell Endocrinol       Date:  2002-07-31       Impact factor: 4.102

Review 3.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Authors:  Stephen R D Johnston; Julia Head; Sunil Pancholi; Simone Detre; Lesley-Ann Martin; Ian E Smith; Mitch Dowsett
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

4.  Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Authors:  Lesley-Ann Martin; Ian Farmer; Stephen R D Johnston; Simak Ali; Chris Marshall; Mitch Dowsett
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

5.  A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.

Authors:  Bin Chen; Bin Su; Shiuan Chen
Journal:  Biochem Pharmacol       Date:  2009-03-26       Impact factor: 5.858

Review 6.  Inhibition of aromatase: insights from recent studies.

Authors:  Richard J Santen
Journal:  Steroids       Date:  2003-09       Impact factor: 2.668

7.  New approaches to the understanding of tamoxifen action and resistance.

Authors:  L M Berstein; H Zheng; W Yue; J-P Wang; A E Lykkesfeldt; F Naftolin; H Harada; M Shanabrough; R J Santen
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

8.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

Authors:  M Baum; A Buzdar; J Cuzick; J Forbes; J Houghton; A Howell; T Sahmoud
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

9.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.

Authors:  Randall E Harris; Rowan T Chlebowski; Rebecca D Jackson; David J Frid; Joao L Ascenseo; Garnet Anderson; Aimee Loar; Rebecca J Rodabough; Emily White; Anne McTiernan
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.

Authors:  S Nakatsugi; T Ohta; T Kawamori; M Mutoh; T Tanigawa; K Watanabe; S Sugie; T Sugimura; K Wakabayashi
Journal:  Jpn J Cancer Res       Date:  2000-09
View more
  6 in total

1.  From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.

Authors:  Bo Zhong; Xiaohan Cai; Snigdha Chennamaneni; Xin Yi; Lili Liu; John J Pink; Afshin Dowlati; Yan Xu; Aimin Zhou; Bin Su
Journal:  Eur J Med Chem       Date:  2011-11-15       Impact factor: 6.514

2.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.

Authors:  Bo Zhong; Snigdha Chennamaneni; Rati Lama; Xin Yi; Werner J Geldenhuys; John J Pink; Afshin Dowlati; Yan Xu; Aimin Zhou; Bin Su
Journal:  J Med Chem       Date:  2013-06-28       Impact factor: 7.446

4.  Identification of selective tubulin inhibitors as potential anti-trypanosomal agents.

Authors:  Rati Lama; Ranjodh Sandhu; Bo Zhong; Bibo Li; Bin Su
Journal:  Bioorg Med Chem Lett       Date:  2012-07-14       Impact factor: 2.823

5.  Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.

Authors:  Arun George Paul; Neelam Sharma-Walia; Bala Chandran
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

6.  Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.

Authors:  Kirti Kandhwal Chahal; Jie Li; Irina Kufareva; Milind Parle; Donald L Durden; Robert J Wechsler-Reya; Clark C Chen; Ruben Abagyan
Journal:  PLoS One       Date:  2019-09-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.